Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib-first versus dacomitinib-first sequencing in EGFR-mutated advanced NSCLC
2019-002869-35Phase 2Active
- Sponsor
- Fondazione Ricerca Traslazionale
- Start
- Feb 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Osimertinib first with Dacomitinib first (2 arms). Primary endpoint: Overall survival by first assigned EGFR-TKI sequence. Started Feb 2021; status: active.
02
Drugs
osimertinibdacomitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2019-002869-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002869-35.